Ariad Pharmaceuticals Upgraded to “Buy” at Maxim Group (ARIA)
Ariad Pharmaceuticals (NASDAQ:ARIA) was upgraded by analysts at Maxim Group to a “buy” rating in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork.com reports. The firm currently has a $11.00 price objective on the stock. Maxim Group’s price target would suggest a potential upside of 26.87% from the company’s current price.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 8.67 on Wednesday. Ariad Pharmaceuticals has a 1-year low of $2.15 and a 1-year high of $23.00. The stock has a 50-day moving average of $7.62 and a 200-day moving average of $9.61. The company’s market cap is $1.610 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last released its earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.07. The company had revenue of $8.28 million for the quarter, compared to the consensus estimate of $6.31 million. On average, analysts predict that Ariad Pharmaceuticals will post $-1.56 earnings per share for the current fiscal year.
ARIA has been the subject of a number of other recent research reports. Analysts at Chardan Capital downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday. Separately, analysts at Jefferies Group raised their price target on shares of Ariad Pharmaceuticals from $7.00 to $8.00 in a research note on Wednesday. Finally, analysts at Credit Suisse set a $8.00 price target on shares of Ariad Pharmaceuticals in a research note on Friday, February 7th. Four investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.82.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.